Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.57 |
| ▸ | CES1 | P23141 | 3/20 | 0.57 |
| ▸ | ACKR3 | P25106 | 9/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31661842 | 1.00 | CES2 (0.57) | CES2CES1ACKR3KMT2AMEN1 | |
| SCHEMBL5084694 | 0.85 | CES2 (0.57) | CES2CES1ACKR3KMT2AMEN1 | |
| SCHEMBL11582932 | 0.84 | HTT (0.49) | CES2CES1ACKR3KMT2AMEN1 | |
| SCHEMBL4707612 | 0.83 | CES2 (0.59) | CES2CES1ACKR3KDM4EALDH1A1 | |
| SCHEMBL14053155 | 0.82 | KMT2A (0.70) | ACKR3KMT2AMEN1HTTKDM4E | |
| SCHEMBL4091424 | 0.82 | HTT (0.62) | CES2CES1ACKR3KMT2AMEN1 | |
| SCHEMBL29788741 | 0.82 | CES2 (0.53) | CES2CES1ACKR3HTTKDM4E | |
| SCHEMBL3892255 | 0.82 | CES2 (0.53) | CES2CES1ACKR3HTTKDM4E | |
| SCHEMBL22097313 | 0.82 | PKM (0.49) | CES2CES1ACKR3KMT2AMEN1 | |
| SCHEMBL20268270 | 0.82 | CES2 (0.53) | CES2CES1ACKR3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2019077627-A1 | A PROCESS FOR THE MANUFACTURE OF POSACONAZOLE | METROCHEM API PVT LTD. (IN) | 2019-04-25 | — | — | WO | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| EP-3060559-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ((3S,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHYL-4-METHYLBENZENESULFONATE | MSN Laboratories Private Limited (IN) | 2016-08-31 | — | — | EP | claimed |
| US-20160237066-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ((3S,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHYL-4-METHYLBENZENESULFONATE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-08-18 | — | — | US | claimed |
| EP-1745004-B1 | ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2016-05-18 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-9035085-B2 | Aryl ketone compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | claimed |
| WO-2015059716-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ((3S,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHYL-4-METHYLBENZENESULFONATE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-04-30 | — | — | WO | claimed |
| US-7691889-B2 | Antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-04-06 | — | — | US | claimed |
| WO-2009141837-A2 | PROCESS FOR PREPARING POSACONAZOLE AND INTERMEDIATES THEREOF | IND-SWIFT LABORATORIES LIMITED (IN) | 2009-11-26 | — | — | WO | claimed |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-07-10 | — | — | US | claimed |
| US-20050192275-A1 | Novel antimycobacterial compounds | LUPIN LIMITED (IN) | 2005-09-01 | — | — | US | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2023173717-A1 | PREPARATION METHOD FOR INTERMEDIATE COMPOUND ACTING AS SYNTHETIC POSACONAZOLE, AND INTERMEDIATE COMPOUND PREPARED THEREBY | 浙江奥翔药业股份有限公司 | 2023-09-21 | — | — | WO | disclosed |
| WO-2019077627-A1 | A PROCESS FOR THE MANUFACTURE OF POSACONAZOLE | METROCHEM API PVT LTD. (IN) | 2019-04-25 | — | — | WO | disclosed |
| WO-2004026848-A1 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPERATION AND THEIR USE AS ANTIMYCOBACTERIAL AGENTS | LUPIN LIMITED (IN) | 2004-04-01 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237066-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ((3S,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHYL-4-METHYLBENZENESULFONATE | CYP4B1, CYP1B1, CYP51A1 | CES2 2157/4885CES1 163/4885ACKR3 4696/4885 |
| US-20050192275-A1 | Novel antimycobacterial compounds | MDH1, IMMT, MLYCD | CES2 4353/4885CES1 4065/4885ACKR3 3724/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | CES2 3438/4885CES1 3038/4885ACKR3 400/4885 |
| US-20080167217-A1 | aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula** Image-1or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, | AKR1C3, AKR1C1, AKR1A1 | CES2 537/4885CES1 85/4885ACKR3 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.